AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05453396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV
Study NCT06376422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spongioflex®
Description: partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.
Study NCT06376422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-operated
Description: no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
Study NCT04810247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Project
Description: The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
Study NCT06514755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GNA followed by GAE
Description: Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.
Study NCT06514755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GAE alone
Description: Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
Study NCT06113341 — intervention group
Intervention type: DRUG
Intervention: IDegLira
Description: Pre-filled pen injection.
Study NCT06505135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem-cell treatment
Description: In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe.
Study NCT06505135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
Study NCT04868851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Here for Health Only
Description: Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
Study NCT04868851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth technology assisted exercise counselling
Description: Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
Study NCT06579404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
Study NCT06579404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy with glucose sensor
Description: Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
Study NCT05726942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthi
Description: Healthi refers to the Healthi app, which is a mobile application for weight loss
Study NCT06368804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic monotherapy treatment and follow-up
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Study NCT06368804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic bitherapy treatment and follow-up
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Study NCT06356974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)
Description: Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
Study NCT04622761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)
Study NCT06646874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR game
Description: Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
Study NCT04748471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccine
Study NCT05615896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging Session
Description: Various scans will be captured on both devices
Study NCT05825547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Description: Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
Study NCT05069844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum chewing for 2 minutes
Description: In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
Study NCT05069844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum chewing for 4 minutes
Description: In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
Study NCT06398171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
Study NCT05310058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester
Study NCT05762471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo
Study NCT05762471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo
Study NCT04412837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical CBD Patch
Description: 35 mg CBD patch
Study NCT06280118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue
Description: Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
Study NCT04412837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Identical patch without active ingredient.
Study NCT00560807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
Study NCT03944902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Dose Escalation
Description: The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
Study NCT03944902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Dose Escalation
Description: If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
Study NCT05095714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver ultrasound and fast-MRI
Description: Half-yearly liver ultrasound and fast-MRI
Study NCT05095714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liver ultrasound
Description: Half-yearly liver ultrasound
Study NCT05615480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypotension guided by cerebral oxygen saturation monitoring
Description: In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
Study NCT04931199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
Study NCT04931199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+App
Description: Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
Study NCT05317221 — intervention group
Intervention type: OTHER
Intervention: Not an extra intervention, tissue taken in routine practice will be used.
Description: No extra intervention: using tumour tissue taken during surgery in standard of care.
Study NCT04063345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Description: Performing intravascular ultrasound before or/and after percutaneous intervention
Study NCT04063345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Performing percutaneous intervention without intravascular ultrasound guidance
Study NCT06217497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
Study NCT05971017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
Study NCT05971017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biostimulated group
Description: Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
Study NCT06645925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Step Protocol
Description: FGG will be done simultaneous with implant placement
Study NCT06645925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Steps Protocol
Description: Conventional FGG protocol, prior to implant placement
Study NCT05317299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 different type of exercise
Description: Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
Study NCT04935762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-103, CST-107, matching placebo
Description: CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as first Tablet Formulation
Description: A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as second Tablet Formulation
Description: A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as first Tablet Formulation
Description: A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as second Tablet Formulation
Description: A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet Formulation
Description: A single dose of PF-07220060 as a tablet formulation administered under fed conditions
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
Description: A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
Description: A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
Study NCT05923411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as third tablet formulation
Description: A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
Study NCT06525662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape
Description: Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
Study NCT06525662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with an arcuate cuff shape
Description: Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
Study NCT05730153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: advanced PRF
Description: advanced PRF+ surgery
Study NCT05730153 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: advanced PRF
Description: advanced PRF+ surgery
Study NCT05615610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spine TENS
Description: The participants in Group A will receive TENS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
Study NCT05615610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
Study NCT05615610 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participants in Group C will receive placebo tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
Study NCT05680831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.070 ppm ozone concentration
Description: The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
Study NCT05680831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clean air (0.0 ppm ozone)
Description: Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
Study NCT05274542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity with blood flow restriction
Description: Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
Study NCT05274542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity without blood flow restriction group
Description: Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
Study NCT05093426 — intervention group
Intervention type: OTHER
Intervention: Stage 2 Digital sleep diary app
Description: Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.